KainosMed and JangsuID Sign MOU for Joint Overseas Entry into AIDS Treatment Market

[Asia Economy Reporter Hyunseok Yoo] Kainosmed announced on the 23rd that it has signed a memorandum of understanding (MOU) with Jiangsu Aidea Pharmaceuticals of China to cooperate for the joint overseas market entry of the AIDS treatment drug (KM-023). The two companies plan to establish a joint venture in the future.

Jiangsu Aidea is developing a new non-nucleoside reverse transcriptase inhibitor (NNRTI) ACC007 based on the technology transfer of Kainosmed's KM-023. Jiangsu Aidea completed Phase 3 clinical trials of ACC007 in China and submitted a new drug application (NDA) to the National Medical Products Administration (NMPA) of China in July.

Recently, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China completed an on-site inspection following the ACC007 NDA application, and final NDA approval is expected after CDE's comprehensive review.

Kainosmed and Jiangsu Aidea decided to enter the global market (excluding Korea and China) through a joint venture based on the promising clinical trial results of ACC007 in China.

A Kainosmed official said, “Our Chinese partner Jiangsu Aidea recently completed an on-site inspection for the new AIDS drug application, bringing it very close to new drug approval in China,” and added, “We expect that cooperation for entering emerging markets will gain momentum through the joint investment of Kainosmed and Jiangsu Aidea.”

This content was produced with the assistance of AI translation services.